Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.38 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.38 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.38 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.37 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.37 |
| ▸ | GMPS | P49915 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311472 | 0.89 | CHKA (0.41) | TRDMT1 | |
| SCHEMBL21311195 | 0.81 | EGFR (0.44) | DOT1L | |
| SCHEMBL21311194 | 0.80 | PI4KA (0.48) | GMPSADORA3ADORA2ASLC28A1 | |
| SCHEMBL21311154 | 0.77 | ADORA3 (0.47) | DOT1LKMT2AGMPSADORA3ADORA2A | |
| SCHEMBL20096938 | 0.77 | DOT1L (0.60) | DOT1LTRDMT1KMT2AEZH2PRMT7 | |
| SCHEMBL23025515 | 0.76 | ADORA3 (0.53) | DOT1LKMT2AGMPSADORA3ADORA2A | |
| SCHEMBL25521510 | 0.76 | ADORA3 (0.53) | DOT1LKMT2AGMPSADORA3ADORA2A | |
| SCHEMBL21311216 | 0.76 | ADORA2A (0.47) | DOT1LKMT2AGMPSADORA3ADORA2A | |
| SCHEMBL21311476 | 0.76 | DOT1L (0.41) | DOT1LGMPSADORA3ADORA2ASLC28A1 | |
| SCHEMBL21311217 | 0.75 | ADORA2A (0.47) | DOT1LKMT2AGMPSADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | DOT1L 2274/4885TRDMT1 28/4885WDR5 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.